Melbourne, Jan 20, 2009 (ABN Newswire) - Regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that it had received Australian institutional ethics approval to begin the first human trial of adult stem cell treatment for prevention of knee osteoarthritis after an acute traumatic knee injury.
